Skip to main content
. 2015 Mar 23;36(4):517–527. doi: 10.1038/aps.2014.157

Figure 3.

Figure 3

ERK, JNK, and p38 MAPK were activated in physalin B-treated cells. (A) Cells were treated with 2.5, 5, and 10 μmol/L physalin B. Samples were collected at 3, 6, 9, 12, 24, and 36 h, separately. Levels of phosphor-ERK, ERK, phosphor-JNK, JNK, phosphor-p38 MAPK, p38 MAPK, and β-actin were detected using Western blotting assay. (B) Cells were treated with 10 μmol/L physalin B with or without p38 MAPK inhibitor SB202190, ERK inhibitor U0126, and JNK inhibitor SP600125. Levels of PARP, p62, and β-actin were detected using Western blotting assay.